Partial reversal of hypoxic pulmonary hypertension by heparin.
Chronic hypoxia produces pulmonary hypertension and an increase in medial thickness of pulmonary arteries that reach maximal values after 10 days of hypoxia. We previously showed that heparin given during the first 10 days of hypoxia reduced the development of both pulmonary hypertension and vascular remodeling in the guinea pig. To determine if heparin could reverse established hypoxic pulmonary hypertension and vascular remodeling, we administered heparin by continuous subcutaneous infusion (20 U/kg/h) for the last 7 days of a 21-day exposure to hypoxia (10% O2, balance N2) and compared these animals with normal saline-infused hypoxic control and room air-exposed animals. Hypoxia increased pulmonary artery pressure from 11 +/- 1 mm Hg (mean +/- SEM) in room air animals to 20 +/- 2 mm Hg (p less than 0.05) in saline-treated hypoxic control animals. Heparin reduced pulmonary artery pressure to 16 +/- 1 mm Hg (p less than 0.05 versus hypoxic control and room air control animals). Total pulmonary resistance (TPR) increased with hypoxia from 0.043 +/- 0.003 mm Hg x min x kg-1 x ml-1 in room air to 0.090 +/- 0.004 in hypoxia (p less than 0.05), and in the rise in TPR was also partially reversed by heparin to 0.068 +/- 0.0003 (p less than 0.05). The percentage of medial thickness of alveolar duct arteries increased from 5.8 +/- 0.6% in room air to 9.5 +/- 0.1% (p less than 0.05) after 3 wk of hypoxia, and heparin therapy partially reversed the increase in medial thickness to 7.2 +/- 0.7% (p less than 0.05 versus both hypoxia control and room air).(ABSTRACT TRUNCATED AT 250 WORDS)
Hassoun
P M
PM
Department of Medicine, Massachusetts General Hospital, Boston 02114.
Thompson
B T
BT
Hales
C A
CA
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000473:pathology; D006168:Guinea Pigs; D006493:Heparin / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D000860:Hypoxia / Q000150:complications*; D008168:Lung / Q000473:pathology; D011650:Pulmonary Alveoli / Q000098:blood supply; D011652:Pulmonary Circulation / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D006493:Heparin